Andere talen Gabather AB

Aandelen

GABA

SE0010869552

Beurs gesloten - Nasdaq Stockholm Andere beurzen 17:29:44 03-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,95 ^SEK	+9,24%		+5,98%	+38,30%

10/04	Gabather AB werkt samen met het Centrum voor Neuropsychiatrisch Schizofrenie Onderzoek in Denemarken om een klinische fase II studie uit te voeren met GT-002	CI
18/03	Gabather AB dient twee nieuwe octrooiaanvragen in voor nieuwe bevindingen over de effecten van GT-002 voor de behandeling van neuropsychiatrische aandoeningen	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Gabather Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct a Clinical Phase II Study with GT-002	10/04
Gabather AB Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct A Clinical Phase II Study with GT-002	10/04
Gabather Submits Two US Patent Applications for GT-002 Use in Psychiatric Disorders	18/03
Gabather files two new patent applications to secure novel findings on the effects of GT-002 for the treatment of psychiatric disorders	18/03
Gabather AB Files Two New Patent Applications to Secure Novel Findings on the Effects of GT-002 for the Treatment of Neuropsychiatric Disorders	18/03
Gabather reports initial positive results from the EEG/fMRI target engagement study	07/03
Gabather AB Reports Initial Positive Results from the EEG/fMRI Target Engagement Study	07/03
Gabather AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	29/02
Gabather AB receives initial EEG data analysis from the GT-002 target engagement study	22/12
Gabather AB initiates discussions with specialist doctors and researchers at Karolinska Institutet for the design of a study in individuals at risk of developing frontotemporal dementia (FTD)	14/12
Gabather AB Approaches a Significant Milestone in the Clinical Development of GT-002	14/12
Gabather AB broadens the scope of EEG data analysis generated during the target engagement study by partnering with MINDIG	11/12
Gabather AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	27/11
Gabather Announces Completion of Phase I EEG/fMRI Target Engagement Study of GT-002 in Healthy Volunteers	12-10-23
Gabather Announces Completion of Phase I EEG/fMRI Target Engagement Study of GT-002 in Healthy Volunteers	12-10-23
Gabather AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	17-08-23
Gabather AB Reports Earnings Results for the First Quarter Ended March 31, 2023	11-05-23
Gabather, Receives Notice of Approval from the Japanese Patent Office (JPO) for its National Phase Application No. 2020-554957	13-04-23
Gabather AB Receives Notice of Approval from the Japanese Patent Office for National Phase Application	13-04-23
Gabather AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	08-02-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Gabather AB

Aandelen

GABA

SE0010869552

Andere talen

Filters